Raindance Technologies and CLC to develop software for resequencing analysis

Sep 18 2009

RainDance Technologies and CLC bio today announced a partnership to develop specialized software for the analysis of targeted resequencing data generated by workflows incorporating RainDance’s Sequence Enrichment Solution and next generation DNA sequencing platforms.

“The rapid and efficient analysis of genomic data plays an important role in searching for the variants in large populations that cause cancer and other devastating diseases,” said Christopher McNary, President and Chief Executive Officer, RainDance Technologies. “By partnering with CLC bio, we can provide researchers with a solution that leverages the power of our innovative microdroplet-based technology to provide the highest quality results in a simple, yet powerful workflow. This capability will help accelerate the advent of personalized medicine and make profound contributions to health and human disease research,” he said.

CLC bio’s Chief Executive Officer, Thomas Knudsen, continues "Having decided to focus on high-throughput sequencing technologies several years ago, we're constantly monitoring the market to identify new and complimentary technologies being developed. The sequence enrichment platform from RainDance Technologies is truly innovative, and we are very much looking forward to making it even more valuable in supporting the full scientific workflow of their customers. We are proud to partner with RainDance on helping global science gain new ground.”

As a first step, CLC bio will release an expansion to its CLC Genomics Workbench, enabling scientists to analyze data faster and more effectively when using the RainDance solution for large scale targeted resequencing studies. The software is already in use by RainDance scientists and will be released for commercial sale later this month.

The CLC bio/RainDance solution can be used with any next-generation sequencing workflow, giving customers the freedom to choose between the Illumina Genome Analyzer, Roche/454, or ABI SOLiD system.

In the future, the partnership will continue to release specialized reports, data analyses, and workflow support for platform independent targeted resequencing research that will provide additional value to RainDance customers.

http://www.clcbio.com/about